Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should

Documenti analoghi

• NOTES: because we can or because we should?
  di: Chand, Manish, et al.
  Pubblicazione: (2008)
• The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
  di: McGraw, K L, et al.
  Pubblicazione: (2015)
• Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
  di: Montalban-Bravo, Guillermo, et al.
  Pubblicazione: (2020)
• Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
  di: Takahashi, Koichi, et al.
  Pubblicazione: (2016)
• TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  di: Sallman, David A., et al.
  Pubblicazione: (2020)